Compare iShares MBS ETF (MBB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MBS ETF trades at $93.39, while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). Which is the better fit depends on your goals.
| MBB | RXRX | |
|---|---|---|
52-Week High | $96.91 | $6.79 |
52-Week Low | $92.92 | $2.84 |
Market Cap | — | $1.53B |
Sector | — | Health |
Enterprise Value | — | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
